On June 19, 2020, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of Outlook Therapeutics, Inc. increased the size of the Board from seven (7) to eight (8) members, and effective upon the Effective Date, appointed Andong Huang to fill the newly created vacancy, with Mr. Huang to serve on the Board as a Class II director until the Company's 2021 annual meeting of stockholders, until his successor has been duly elected and qualified, or until his earlier death, resignation or removal. Mr. Huang is the Vice President, Business Development of Syntone Technologies Co. Ltd., an affiliate of Syntone Ventures LLC.